Morepen Laboratories Limited (IN:MOREPENLAB)
:MOREPENLAB
Want to see IN:MOREPENLAB full AI Analyst Report?
MOREPENLAB Stock Chart & Stats
₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)
Day’s Range― - ―
52-Week Range₹33.42 - ₹70.40
Previous CloseN/A
Volume3.34M
Average Volume (3M)88.30K
Market Cap
₹25.10B
Enterprise Value₹25.08B
Total Cash (Recent Filing)₹932.86M
Total Debt (Recent Filing)₹1.58B
Price to Earnings (P/E)26.9
Beta1.74
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)1.79
Shares Outstanding547,953,700
10 Day Avg. Volume126,704
30 Day Avg. Volume88,304
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)1.64
Price to Sales (P/S)1.13
P/FCF Ratio-14.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business DiversificationHaving APIs, finished formulations and consumer healthcare creates multiple durable revenue streams across B2B and B2C channels. This mitigates concentration risk, enables cross-selling and access to domestic and export markets, and supports resilience through product-portfolio balance over months.
Profitability RecoverySustained improvement in profitability since the 2023 trough indicates operational improvements or better product mix that can persist. Stronger gross and operating margins provide more durable earnings power, supporting reinvestment, buffer against shocks and potential for consistent cash generation if conversion improves.
Moderate Leverage And Equity BaseA sizable, growing equity base and moderate leverage offer balance-sheet flexibility for funding capex, working capital or M&A without immediate distress. This structural strength improves access to capital markets and provides a cushion against operational volatility over the coming months.
Bears Say
Weak Cash ConversionPersistent negative free cash flow and weak operating cash conversion undermine the firm's ability to self-fund capex, service debt, or return capital. Over 2–6 months this increases reliance on external financing, elevates refinancing risk, and questions sustainability of reported earnings quality.
Revenue Decline & VolatilityMaterial year-over-year revenue decline and volatility reduce scale economics and weaken pricing leverage. A shrinking or inconsistent top line limits margin expansion, complicates forecasting and strategic investments, and raises the risk that recent profitability gains are not durable without revenue stabilization.
Rising Debt And Margin PressureA material uptick in debt combined with compressing operating and net margins tightens financial flexibility and increases interest burden. Over the medium term this can crowd out investment, heighten leverage risk if cash conversion remains weak, and make the firm more vulnerable to cost or demand shocks.
Morepen Laboratories Limited News
MOREPENLAB FAQ
What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹70.40 in the past 12 months.
What is Morepen Laboratories Limited’s market cap?
Morepen Laboratories Limited’s market cap is ₹25.10B.
When is Morepen Laboratories Limited’s upcoming earnings report date?
Morepen Laboratories Limited’s upcoming earnings report date is Jul 23, 2026 which is in 48 days.
How were Morepen Laboratories Limited’s earnings last quarter?
Morepen Laboratories Limited released its earnings results on May 22, 2026. The company reported ₹0.28 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.28.
Is Morepen Laboratories Limited overvalued?
According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.49%. See more information on Morepen Laboratories Limited dividends here
What is Morepen Laboratories Limited’s EPS estimate?
Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morepen Laboratories Limited have?
Morepen Laboratories Limited has 547,953,700 shares outstanding.
What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
Morepen Laboratories Limited reported an EPS of ₹0.28 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.325%.
Which hedge fund is a major shareholder of Morepen Laboratories Limited?
Currently, no hedge funds are holding shares in IN:MOREPENLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.
Technical Analysis
Alembic Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Solara Active Pharma Sciences Ltd.
―
Windlas Biotech Ltd.
―